{
  "id": 11237341,
  "title": "Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?",
  "url": "https://urgent.news/2026/10/01/royalty-pharma-owns-a-piece-of-16-blockbuster-drugs-is-the-stock-a-buy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T16:30:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/10/01/royalty-pharma-owns-a-piece-of-16-blockbuster-drug/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Royalty Pharma (NASDAQ: RPRX) offers investors a unique opportunity to gain exposure to both existing and future blockbuster drugs. This distinct approach positions the company between biotech stocks and traditional pharmaceutical companies, allowing for a diversified portfolio. Royalty Pharma operates as both a biopharma firm and a venture capital entity, investing in both established drug manufacturers and nonprofit researchers like universities. In return for their financial support, the company receives a stake in the drugs they develop or are still in the research phase.\n\nDespite the company's stock being priced at a relatively low valuation, the potential upside is considerable due to its ownership in 16 blockbuster drugs and a number of promising drug candidates. This combination of established and emerging opportunities suggests that Royalty Pharma may be a hidden gem within the healthcare sector, yet to receive the attention it deserves from market participants.",
  "summary": "Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}